In this article
FDA Approval of Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma
August 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) has been given accelerated approval by the Food and Drug Administration for the treatment of adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, including proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody.
MonumenTAL-1 Clinical Trial: Efficacy and Response Rates
A single-arm, open-label, multicenter research called MMY1001 (MonumenTAL-1) (NCT03399799, NCT4634552) that included 187 patients who had previously had at least four systemic medications assessed the efficacy of the treatment. Following two step-up doses in the first week of therapy, patients received talquetamab-tgvs 0.4 mg/kg subcutaneously weekly or talquetamab-tgvs 0.8 mg/kg subcutaneously biweekly (every two weeks), following three step-up doses, until disease progression or intolerable toxicity.
Overall response rate (ORR) and duration of response (DOR), which were evaluated by an independent review committee based on IMWG guidelines, were the primary efficacy outcome measures. Patients who had previously had at least four lines of therapy, such as a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody, made up the primary efficacy population. The median DOR was 9.5 months (95% CI: 6.5, not estimable) and the ORR in the 100 patients taking 0.4 mg/kg weekly was 73% (95% confidence interval (CI): 63.2%, 81.4%). The median DOR in the 87 patients taking 0.8 mg/kg biweekly was not estimable, while the ORR was 73.6% (95% CI: 63%, 82.4%). About 85% of respondents reportedly continued to respond for at least nine months.
Safety Precautions: Boxed Warnings, REMS, and Side Effects
A Boxed Warning for immunological effector cell-associated neurotoxicity (ICANS) and neurologic toxicity, including life-threatening or lethal cytokine release syndrome (CRS), is included in the prescribing material for talquetamab-tgvs. Talquetamab-tgvs is only offered in a restricted programme under a Risk Evaluation and Mitigation Strategy (REMS), known as the Tecvayli-Talvey REMS, due to the risks of CRS and neurologic toxicity, including ICANS.
The 339 patients in the safety population experienced CRS, dysgeusia, nail disorder, musculoskeletal discomfort, skin disorder, rash, exhaustion, loss of weight, dry mouth, pyrexia, xerosis, dysphagia, upper respiratory tract infection, diarrhoea, and adverse events in that order ( 20%).
Talquetamab-tgvs should be administered at a dose of either 0.4 mg/kg weekly or 0.8 mg/kg biweekly. The complete dose schedules are listed in the prescribing information.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.